Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age
Clinical trial NCT04782895 · COMPLETED
Trial details
- NCT number
- NCT04782895
- Sponsor
- Xiamen University
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-14
- Primary completion
- 2022-05-30
- Enrollment
- 488
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.